MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07677475 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

65

Enrollment

OTHER_GOV

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: MRG003 (Becotatug vedotin) and Toripalimab
DRUG: Toripalimab

Sponsor

Dongguan People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]